The Canadian cannabis company, Organigram, a leading innovator in medical and recreational indoor crops, will start marketing four of their most popular high-quality and products in Israel this week. The firm sees the Israeli cannabis market as a great opportunity to expand their business and expects to create a positive reputation thanks to their selected cannabis products.
Starting from this Tuesday and throughout the month, 4 quality cannabis strains from the Canadian company ‘Organigram’ will arrive at the pharmacies in Israel – one of the world-famous cannabis companies and one that is considered an expert in indoor crops that allow optimal accuracy of growing conditions.
‘Organigram’, which has been operating in the Canadian market for about 7 years in the medical cannabis industry, also entered the legal leisure market in 2019. They started out with the intention of marketing only organic cannabis, hence their name.
The company’s growing facility, in the province of New Brunswick in Canada, covers an area of 56 acres and consists of 3 floors of plants that receive the same metrics of light, humidity, temperature and fertilizer. The facility supplies about 80 tons of what they call ‘premium cannabis’ a year.
Julie Chamberlain, Deputy Director of Marketing at Organigram, said that the company sees the Israeli market as a primary target. Accordingly, she said, they sent to Israel their most popular varieties, and of the highest quality, identical to that sold in Canada.
If you want to know more about the cannabis market, how Canadian companies are starting to sell their products in Israel, and to find out the latest cannabis news, download the Hemp.im mobile application.
Organigram focus on high quality cannabis products
“We grow varieties under micro-climatic conditions specific to them, with temperature, air movement, light and humidity tailor-made to reach the ideal conditions for all genetics and thus reach its maximum potential in apartments and regularly”, Chamberliain explains.
According to a report submitted by Organigram to Nasdaq, more than $200 million was recently invested in the growth facility, including the construction of 3 growth floors that will allow them to significantly reduce production costs, and accordingly the price of its products to consumers in Israel.
“The quality of flowering buds we sent to Israel is just like the one sold in Canada”, she reassures in response to rumors that 10 tons of cannabis from other companies imported to Israel so far in 2020 are mostly “leftovers” that have not been sold in Canada or Europe.
“The varieties we sent to Israel are considered ‘Top Shelf’ products in the medical market in Canada”, she promises. “Together with ‘Canndoc’, we selected our 4 most popular varieties, in order to present a complete portfolio of quality cannabis to patients in Israel as well.”
A variety of Canadian cannabis will hit stores in this week
Two of the four varieties will be marketed this week in selected stores ‘Ultra Sour – Sativa T20’ considered the company’s most popular, and ‘Kanata – indica T20’ rich in terpenes.
Later this month two other varieties will reach stores: ‘Acadia – T20 Sativa’ and ‘Hash Plant – Indica T20’. Prices for both varieties will be in between $87 and $91 (295-309 NIS).
The Organigram varieties were brought to Israel as part of a 7½-year cooperation agreement with the Israeli company Canndoc. These varieties, and others that will arrive in the coming months and years, are marketed under the branding of a new series called ‘Canndoc Indoor’.
The Canndoc Indoor series joins the previous series, ‘Canndoc Diamond ‘, which was launched in partnership with another large Canadian cannabis company, ‘Tillery’. Soon Canndoc is preparing to launch a third series, ‘Canndoc Utopia’.
Some details on the new products hitting Isreali shelves
Chamberlain provided details about each of the 4 new strains. She emphasizes that these are varieties rich in Terpenes, the components responsible for the taste and smell of cannabis, and are found in these varieties in a relatively high amount of about 1.5% -2%.
Ultra Sour – Siva T20
‘Ultra Sour’’ is, according to Chamberlain, the most popular strain of Organigram, a THC-rich and juicy sativa dominant with an aroma of a sour-sweet taste (1.4% terpenes). “This is our best-selling variety and is rated as a top-pull product in Canada,” she emphasizes.
Kanata – Indica T20
‘Kanata’, named after one of the first Native American tribes to settle Canada, is, according to Chamberlain, a dominant Indica-purple variety, with a sweet scent reminiscent of roses and apples (1.9% terpenes), and boasting highly compacted and fleshy flowers.
The genetic origin of ‘kanata’ is in the hybridization between two well-known and very popular strains and contains between 18.5% and 20.3% THC.
Acadia – Sativa T20
‘Acadia’ is a dominant Sativa variety known for its dense, trichrome-dense inflorescences, and its earthy pungent-sweet aroma (1.6% terpenes). It is named after a historic region located in the eastern part of Canada, in the territory of present-day Quebec Province.
Hash Plant – Indica T20
According to Chamberlain, a very dense Indica dominant variety, known for its sweet, cherry aroma, and emerald hue (1.2% terpenes). In addition, she notes that the strain has a ‘heavy’ effect physically and mentally, and is therefore suitable for the evening hours.
The impact characteristics of the variety, along with an aroma that is said to be reminiscent of Afghan cannabis, are what have earned it the nickname ‘Hash Plant’. It contains 17.4% -18.4% THC and among its members of the ‘Canndoc Indoor’ series will be the last to hit stores, probably only in about three weeks or more.
Finally, Chamberlain would like to emphasize once again that Organigram is entering the Israeli cannabis market with the sincere intention of exposing cannabis patients in Israel to premium products, in order to establish a regular and loyal customer base here. Time will tell if her wish will come true.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in קנאביס, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.